All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES metastasis (liver )
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
Extensive stage SCLC (Es-SCLC) - 1st Line (L1), atezolizumab plus SoC vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpower-133, 2018 0.70 [0.54; 0.91]
0.70 [0.54 ; 0.91 ] IMpower-133, 2018 1 0% 403 NA not evaluable deaths (OS) (extension)detailed results IMpower-133, 2018 0.76 [0.60; 0.96]
0.76 [0.60 ; 0.96 ] IMpower-133, 2018 1 0% 403 NA not evaluable PFS (extension)detailed results IMpower-133, 2018 0.77 [0.63; 0.95]
0.77 [0.63 ; 0.95 ] IMpower-133, 2018 1 0% 403 NA not evaluable progression or deaths (PFS)detailed results IMpower-133, 2018 0.77 [0.62; 0.96]
0.77 [0.62 ; 0.96 ] IMpower-133, 2018 1 0% 403 NA not evaluable objective responses (ORR)detailed results IMpower-133, 2018 0.84 [0.56; 1.25]
0.84 [0.56 ; 1.25 ] IMpower-133, 2018 1 0% 403 NA not evaluable objective responses (ORR) (extension)detailed results IMpower-133, 2018 0.84 [0.56; 1.25]
0.84 [0.56 ; 1.25 ] IMpower-133, 2018 1 0% 403 NA not evaluable AE (any grade)detailed results IMpower-133, 2018 14.63 [0.82; 259.59]
14.63 [0.82 ; 259.59 ] IMpower-133, 2018 1 0% 394 NA not evaluable AE (grade 3-4)detailed results IMpower-133, 2018 1.16 [0.77; 1.76]
1.16 [0.77 ; 1.76 ] IMpower-133, 2018 1 0% 394 NA not evaluable AE leading to death (grade 5)detailed results IMpower-133, 2018 0.35 [0.11; 1.11]
0.35 [0.11 ; 1.11 ] IMpower-133, 2018 1 0% 394 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpower-133, 2018 3.96 [1.57; 9.99]
3.96 [1.57 ; 9.99 ] IMpower-133, 2018 1 0% 394 NA not evaluable SAE (any grade)detailed results IMpower-133, 2018 1.12 [0.74; 1.70]
1.12 [0.74 ; 1.70 ] IMpower-133, 2018 1 0% 394 NA not evaluable STRAE (any grade)detailed results IMpower-133, 2018 1.26 [0.78; 2.06]
1.26 [0.78 ; 2.06 ] IMpower-133, 2018 1 0% 394 NA not evaluable TRAE (any grade)detailed results IMpower-133, 2018 1.56 [0.68; 3.56]
1.56 [0.68 ; 3.56 ] IMpower-133, 2018 1 0% 394 NA not evaluable TRAE (grade 3-4)detailed results IMpower-133, 2018 1.02 [0.68; 1.52]
1.02 [0.68 ; 1.52 ] IMpower-133, 2018 1 0% 394 NA not evaluable TRAE leading to death (grade 5)detailed results IMpower-133, 2018 0.99 [0.20; 4.96]
0.99 [0.20 ; 4.96 ] IMpower-133, 2018 1 0% 394 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
3.99 [0.18 ; 89.04 ] IMpower-133, 2018 1 0% 394 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
0.99 [0.02 ; 50.14 ] IMpower-133, 2018 1 0% 394 NA not evaluable Alopecia TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
0.99 [0.02 ; 50.14 ] IMpower-133, 2018 1 0% 394 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMpower-133, 2018 1.18 [0.66; 2.12]
1.18 [0.66 ; 2.12 ] IMpower-133, 2018 1 0% 394 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
3.99 [0.18 ; 89.04 ] IMpower-133, 2018 1 0% 394 NA not evaluable Constipation TRAE (grade 3-4)detailed results IMpower-133, 2018 1.98 [0.07; 59.51]
1.98 [0.07 ; 59.51 ] IMpower-133, 2018 1 0% 394 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
3.99 [0.18 ; 89.04 ] IMpower-133, 2018 1 0% 394 NA not evaluable Diabetes TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
0.99 [0.02 ; 50.14 ] IMpower-133, 2018 1 0% 394 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results IMpower-133, 2018 4.02 [0.45; 36.30]
4.02 [0.45 ; 36.30 ] IMpower-133, 2018 1 0% 394 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMpower-133, 2018 3.00 [0.31; 29.09]
3.00 [0.31 ; 29.09 ] IMpower-133, 2018 1 0% 394 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMpower-133, 2018 0.48 [0.18; 1.30]
0.48 [0.18 ; 1.30 ] IMpower-133, 2018 1 0% 394 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpower-133, 2018 1.98 [0.07; 59.51]
1.98 [0.07 ; 59.51 ] IMpower-133, 2018 1 0% 394 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpower-133, 2018 6.02 [0.30; 120.88]
6.02 [0.30 ; 120.88 ] IMpower-133, 2018 1 0% 394 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
0.99 [0.02 ; 50.14 ] IMpower-133, 2018 1 0% 394 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
0.99 [0.02 ; 50.14 ] IMpower-133, 2018 1 0% 394 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
0.99 [0.02 ; 50.14 ] IMpower-133, 2018 1 0% 394 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpower-133, 2018 4.02 [0.45; 36.30]
4.02 [0.45 ; 36.30 ] IMpower-133, 2018 1 0% 394 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results IMpower-133, 2018 1.25 [0.48; 3.24]
1.25 [0.48 ; 3.24 ] IMpower-133, 2018 1 0% 394 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.06; 15.94]
0.99 [0.06 ; 15.94 ] IMpower-133, 2018 1 0% 394 NA not evaluable Nephritis TRAE (grade 3-4)detailed results IMpower-133, 2018 1.98 [0.07; 59.51]
1.98 [0.07 ; 59.51 ] IMpower-133, 2018 1 0% 394 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMpower-133, 2018 0.91 [0.57; 1.44]
0.91 [0.57 ; 1.44 ] IMpower-133, 2018 1 0% 394 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMpower-133, 2018 0.49 [0.04; 5.47]
0.49 [0.04 ; 5.47 ] IMpower-133, 2018 1 0% 394 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results IMpower-133, 2018 0.33 [0.03; 3.17]
0.33 [0.03 ; 3.17 ] IMpower-133, 2018 1 0% 394 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
3.99 [0.18 ; 89.04 ] IMpower-133, 2018 1 0% 394 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results IMpower-133, 2018 6.02 [0.30; 120.88]
6.02 [0.30 ; 120.88 ] IMpower-133, 2018 1 0% 394 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpower-133, 2018 0.49 [0.04; 5.47]
0.49 [0.04 ; 5.47 ] IMpower-133, 2018 1 0% 394 NA not evaluable Rash TRAE (grade 3-4)detailed results IMpower-133, 2018 8.06 [0.42; 153.52]
8.06 [0.42 ; 153.52 ] IMpower-133, 2018 1 0% 394 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
0.99 [0.02 ; 50.14 ] IMpower-133, 2018 1 0% 394 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMpower-133, 2018 1.36 [0.67; 2.73]
1.36 [0.67 ; 2.73 ] IMpower-133, 2018 1 0% 394 NA not evaluable Vomiting TRAE (grade 3-4)detailed results IMpower-133, 2018 0.66 [0.11; 3.97]
0.66 [0.11 ; 3.97 ] IMpower-133, 2018 1 0% 394 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:36 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 162
- treatments: 866